<p>Prime Medicine（纳斯达克代码：PRME - 获取免费报告）在周一发布的报告中被 Wall Street Zen 的分析师从 “卖出” 评级下调至 “强烈卖出” 评级。</p>
<p>获取 <strong>Prime Medicine</strong> 警报：</p>
<p>其他一些券商也对 PRME 发表了看法。Weiss Ratings 在 12 月 29 日的报告中重申了对 Prime Medicine 股票的 “卖出（d-）” 评级。Lifesci Capital 在 3 月 2 日的报告中将 Prime Medicine 的股票评级上调至 “强烈买入”。最后，Oppenheimer 在 3 月 12 日的报告中开始覆盖 Prime Medicine 的股票。他们对该股票设定了 “跑赢大盘” 评级和 11.00 美元的目标价。一位分析师给予该股票 “强烈买入” 评级，四位分析师给予 “买入” 评级，三位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 7.38 美元。</p>
<p><strong>查看我们关于 PRME 的最新研究报告</strong></p>
<h2>Prime Medicine 价格表现</h2>
<p>周一，PRME 的股票开盘价为 3.70 美元。该公司的市值为 6.6829 亿美元，市盈率为-2.74，贝塔值为 2.65。公司的 50 日移动平均线为 3.69 美元，200 日移动平均线为 3.96 美元。Prime Medicine 的 52 周低点为 1.11 美元，52 周高点为 6.94 美元。</p>
<h2>对 Prime Medicine 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Pictet Asset Management Holding SA 在第一季度以 42,000 美元的估值收购了 Prime Medicine 的股票。Rockefeller Capital Management L.P.在第四季度将其在 Prime Medicine 的持股提高了 10,557.7%。Rockefeller Capital Management L.P.目前拥有 121,391 股该公司的股票，估值为 421,000 美元，此前在上个季度又收购了 120,252 股。Caitong International Asset Management Co. Ltd 在第四季度以 134,000 美元的估值收购了 Prime Medicine 的股票。Chelsea Counsel Co.在第四季度将其在 Prime Medicine 的持股提高了 9.0%。Chelsea Counsel Co.目前拥有 227,000 股该公司的股票，估值为 788,000 美元，此前在上个季度又收购了 18,790 股。最后，Virtu Financial LLC 在第四季度将其在 Prime Medicine 的持股提高了 701.2%。Virtu Financial LLC 目前拥有 94,778 股该公司的股票，估值为 329,000 美元，此前在上个季度又收购了 82,948 股。机构投资者和对冲基金持有该公司 70.37% 的股票。</p>
<h2>Prime Medicine 公司简介</h2>
<p>（获取免费报告）</p>
<p>我们是一家生物技术公司，致力于提供一种新型的差异化一次性治愈基因疗法——Prime Editors，以通过部署我们的 Prime Editing 技术来解决最广泛的疾病谱系。我们认为这是一种多功能、精确、高效且广泛的基因编辑技术。与疾病相关的基因突变多种多样，可能从单个碱基的错误（称为点突变）到超出单个碱基的错误，如插入、缺失、重复或其组合。</p>
<h2>另请参见</h2>
<ul>
<li>我们更看好的五只股票，而不是 Prime Medicine</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJNRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJNRQ"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
<p>在你考虑 Prime Medicine 之前，你需要听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Prime Medicine 并不在名单上。</p>
<p>虽然 Prime Medicine 目前在分析师中有 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRME

标普生物技术 3 倍做多 - Direxion

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

IBBQ

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>华尔街禅将 Prime Medicine（NASDAQ:PRME）的评级从 “卖出” 下调至 “强烈卖出”。其他券商的意见不一，Weiss Ratings 维持 “卖出（d-）” 评级，而 Lifesci Capital 则上调至 “强力买入”。该股票的共识评级为 “适度买入”，平均目标价为 7.38 美元。PRME 开盘价为 3.70 美元，市值为 6.6829 亿美元。机构投资者持有该股票的 70.37%，尽管评级下调，但仍反映出显著的投资兴趣</p>

<p>Prime Medicine (NASDAQ:PRME - Get Free Report) was downgraded by analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a report issued on Monday.</p>
<div class="lb-trans"><p>Prime Medicine（纳斯达克代码：PRME - 获取免费报告）在周一发布的报告中被 Wall Street Zen 的分析师从 “卖出” 评级下调至 “强烈卖出” 评级。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Prime Medicine</strong> 警报：</p>
</div><p>A number of other brokerages have also weighed in on PRME. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Prime Medicine in a report on Monday, December 29th. Lifesci Capital upgraded shares of Prime Medicine to a &#34;strong-buy&#34; rating in a report on Monday, March 2nd. Finally, Oppenheimer assumed coverage on shares of Prime Medicine in a report on Thursday, March 12th. They set an &#34;outperform&#34; rating and a $11.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $7.38.</p>
<div class="lb-trans"><p>其他一些券商也对 PRME 发表了看法。Weiss Ratings 在 12 月 29 日的报告中重申了对 Prime Medicine 股票的 “卖出（d-）” 评级。Lifesci Capital 在 3 月 2 日的报告中将 Prime Medicine 的股票评级上调至 “强烈买入”。最后，Oppenheimer 在 3 月 12 日的报告中开始覆盖 Prime Medicine 的股票。他们对该股票设定了 “跑赢大盘” 评级和 11.00 美元的目标价。一位分析师给予该股票 “强烈买入” 评级，四位分析师给予 “买入” 评级，三位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 7.38 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on PRME</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 PRME 的最新研究报告</strong></p>
</div><h2>Prime Medicine Price Performance</h2>
<div class="lb-trans"><h2>Prime Medicine 价格表现</h2>
</div><p>Shares of PRME opened at $3.70 on Monday. The firm has a market cap of $668.29 million, a PE ratio of -2.74 and a beta of 2.65. The company's fifty day moving average is $3.69 and its two-hundred day moving average is $3.96. Prime Medicine has a fifty-two week low of $1.11 and a fifty-two week high of $6.94.</p>
<div class="lb-trans"><p>周一，PRME 的股票开盘价为 3.70 美元。该公司的市值为 6.6829 亿美元，市盈率为-2.74，贝塔值为 2.65。公司的 50 日移动平均线为 3.69 美元，200 日移动平均线为 3.96 美元。Prime Medicine 的 52 周低点为 1.11 美元，52 周高点为 6.94 美元。</p>
</div><h2>Hedge Funds Weigh In On Prime Medicine</h2>
<div class="lb-trans"><h2>对 Prime Medicine 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in the business. Pictet Asset Management Holding SA acquired a new position in shares of Prime Medicine during the 1st quarter valued at $42,000. Rockefeller Capital Management L.P. lifted its holdings in shares of Prime Medicine by 10,557.7% during the 4th quarter. Rockefeller Capital Management L.P. now owns 121,391 shares of the company's stock valued at $421,000 after acquiring an additional 120,252 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Prime Medicine during the 4th quarter valued at $134,000. Chelsea Counsel Co. lifted its holdings in shares of Prime Medicine by 9.0% during the 4th quarter. Chelsea Counsel Co. now owns 227,000 shares of the company's stock valued at $788,000 after acquiring an additional 18,790 shares in the last quarter. Finally, Virtu Financial LLC lifted its holdings in shares of Prime Medicine by 701.2% during the 4th quarter. Virtu Financial LLC now owns 94,778 shares of the company's stock valued at $329,000 after acquiring an additional 82,948 shares in the last quarter. Institutional investors and hedge funds own 70.37% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对该公司的持仓进行了调整。Pictet Asset Management Holding SA 在第一季度以 42,000 美元的估值收购了 Prime Medicine 的股票。Rockefeller Capital Management L.P.在第四季度将其在 Prime Medicine 的持股提高了 10,557.7%。Rockefeller Capital Management L.P.目前拥有 121,391 股该公司的股票，估值为 421,000 美元，此前在上个季度又收购了 120,252 股。Caitong International Asset Management Co. Ltd 在第四季度以 134,000 美元的估值收购了 Prime Medicine 的股票。Chelsea Counsel Co.在第四季度将其在 Prime Medicine 的持股提高了 9.0%。Chelsea Counsel Co.目前拥有 227,000 股该公司的股票，估值为 788,000 美元，此前在上个季度又收购了 18,790 股。最后，Virtu Financial LLC 在第四季度将其在 Prime Medicine 的持股提高了 701.2%。Virtu Financial LLC 目前拥有 94,778 股该公司的股票，估值为 329,000 美元，此前在上个季度又收购了 82,948 股。机构投资者和对冲基金持有该公司 70.37% 的股票。</p>
</div><h2>Prime Medicine Company Profile</h2>
<div class="lb-trans"><h2>Prime Medicine 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.</p>
<div class="lb-trans"><p>我们是一家生物技术公司，致力于提供一种新型的差异化一次性治愈基因疗法——Prime Editors，以通过部署我们的 Prime Editing 技术来解决最广泛的疾病谱系。我们认为这是一种多功能、精确、高效且广泛的基因编辑技术。与疾病相关的基因突变多种多样，可能从单个碱基的错误（称为点突变）到超出单个碱基的错误，如插入、缺失、重复或其组合。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参见</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Prime Medicine</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJNRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=PRME"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Prime Medicine 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每日推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Prime Medicine 并不在名单上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prime Medicine 目前在分析师中有 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Prime Medicine (NASDAQ:PRME) Stock Rating Lowered by Wall Street Zen

Market Beat

Prime Medicine

Invesco Nasdaq Biotechnology ETF

奥本海默控股

财通证券

Virtu Finc

Prime Medicine（纳斯达克股票代码：PRME）的股票评级被华尔街 Zen 下调